Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
1 clinical trials · Condition
◉ Watch Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719) | Roswell Park Cancer Institute | 2018-03-27 |
Track Blasts 30 Percent or Less of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.